The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
2022 · The Canadian Journal of Psychiatry · 54 citations
https://doi.org/10.1177/07067437221111371
K
Kyle T. Greenway
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
58
Papers
795
Citations
17
h-index
25
i10-index
Kyle T. Greenway is an academic researcher from Jewish General Hospital. The author has contributed to research in topics: Psychedelics and Drug Studies & Treatment of Major Depression & Chemical synthesis and alkaloids. The author has an h-index of 17, co-authored 50 publications.
ORCID: 0000-0002-7829-493XPapers by this author
worksCountertransference towards suicidal patients: a systematic review
2021 · Current Psychology · 37 citations
https://doi.org/10.1007/s12144-021-01424-0
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024 · EClinicalMedicine · 37 citations
https://doi.org/10.1016/j.eclinm.2024.102799
Psychological pain and depression: it’s hard to speak when it hurts
2020 · International Journal of Psychiatry in Clinical Practice · 18 citations
https://doi.org/10.1080/13651501.2020.1836225
An international Delphi consensus for reporting of setting in psychedelic clinical trials
2025 · Nature Medicine · 18 citations
https://doi.org/10.1038/s41591-025-03685-9
Hounsfield unit
2015 · Radiopaedia.org · 12 citations
https://doi.org/10.53347/rid-38181
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat